StockStory.org on MSN
Pfizer earnings: What to look for from PFE
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors ...
Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.
Pfizer Inc. (NYSE:PFE) ranks among the best low-risk investments in May 2026. On April 13, Guggenheim reaffirmed a Buy rating ...
The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast cancer drug for patients with an ...
Pfizer (PFE) stock and Arvinas (ARVN) stock are in focus as the FDA approves the companies' breast cancer drug, Veppanu. Read ...
VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...
Pfizer Inc. (NYSE: PFE) is one of the 10 Best Medical Stocks to Buy Under $30. On April 20, Pfizer Inc. (NYSE:PFE) announced, ...
(NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO ® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM ...
The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question ...
Pfizer said on Tuesday it has settled patent disputes with three generic drugmakers over its blockbuster heart drug Vyndamax ...
Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...
The stock is down on a predictable, already-announced Entresto patent cliff (Entresto -42% YoY in Q1) and the market is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results